Catalyst Pharmaceuticals Inc. (CPRX)
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Catalyst Pharmaceutics to Report Q1 Earnings: Is a Beat in the Cards?
CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.
Catalyst Pharmaceutical (CPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Does Catalyst (CPRX) Have the Potential to Rally 28.87% as Wall Street Analysts Expect?
The mean of analysts' price targets for Catalyst (CPRX) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
Catalyst (CPRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Predict a 45.3% Upside in Catalyst (CPRX): Here's What You Should Know
The mean of analysts' price targets for Catalyst (CPRX) points to a 45.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
